by New research indicates that two distinct medication classes, Sodium-Glucose Co-Transporters 2 (SGLT2) inhibitors and Glucagon-Like Peptide-1 (GLP-1) receptor agonists, significantly decrease the risk of cardiovascular and liver events in people diagnosed with Type 2 Diabetes (T2D).
According to a recent meta-analysis published in The Lancet, individuals with T2D who took SGLT2 inhibitors experienced a 39% lower risk of major adverse cardiovascular events (MACE), including heart attacks, strokes, and Cardiovascular Devices deaths, compared to those who did not receive the treatment. Furthermore, the study revealed a 32% reduction in the risk of all-cause mortality.
Additionally, the research found that GLP-1 receptor agonists were associated with a 26% lower risk of MACE and a 35% reduction in the risk of all-cause mortality. These findings were based on a total of 28,000 participants from various clinical trials.
The researchers emphasized that these medications not only help manage blood sugar levels but also provide additional benefits for cardiovascular and liver health. They encouraged healthcare professionals to consider prescribing these classes of medications to their T2D patients to reduce the risk of complications.
In conclusion, the latest research highlights the importance of SGLT2 inhibitors and GLP-1 receptor agonists in managing Type 2 Diabetes and preventing cardiovascular and liver events. These medications offer significant benefits beyond blood sugar control, making them valuable tools in the fight against diabetes-related complications.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
